Latest

• Patented Medicines Expenditure in Canada 1990-2018

  Are government price controls justified by the cost of innovative pharmaceuticals? CHPI RESEARCH REPORT »

• Canada’s Vaccine Development Capacity and the Federal Government’s Management of COVID-19

  Paul Lucas, Retired President and CEO GlaxoSmithKline. »

• E-Mental Health Services and Unmet Needs of Canadians

  Opportunities to Improve Mental Health During and After COVID-19 Pandemic. Mark Embrett, PhD. »

• Career Options and Professional Integration of Internationally Trained Physicians in Canada.

  Could International Medical Graduates solve our shortage of healthcare professionals in Canada? Sanjida Newaz, MBBS, MSc. »

• Universal public funding for dental care in Canada: problems, policies, and politics.

  Should dental care be funded like medicare? Homam Albaghdadi, DDS. »

• Ensuring early access to a COVID-19 vaccine in Canada.

  Policy solutions include Regulatory Harmonization, Fair Market Prices, and Intellectual Property Rights. Brett Skinner, PhD. »

• Vaccines policy in Canada: International and Domestic Comparisons.

  This paper compares the policy environments for vaccines in Canada, Australia, United Kingdom, New Zealand, and the United States. Brett Skinner, PhD. »

• Evidence that regulating pharmaceutical prices negatively affects R&D and access to new medicines.

  A systematic literature review. Yanick Labrie, MSc. »

• COVID-19 Economic Costs and the Implicit Value of a Life-Year in Canada.

  UPDATED Economic value of a life-year implied by the government policy response to COVID-19 exceeds the cost effectiveness thresholds used by CADTH and PMPRB. Brett Skinner, PhD. »